Dogwood Therapeutics Launches $8.56M At-The-Market Stock Offering Under New Equity Distribution Agreement

On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Equity Distribution Agreement (the "Agreement") with Northland Securities, Inc. (trade name Northland Capital Markets), as sales agent (the "Sales Agent"), relating to the issuance and sale from time to time by the Company (the "ATM Program"), through the Sales Agent, of shares of the Company's common stock, par value $0.0001 per share, having an aggregate offering price of up to $8,558,712 (the "Shares"). Sales of the Shares, if any, under the Agreement will be made in sales deemed to be "at-the-market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), as agreed with the Sales Agent. In accordance with the applicable rules of the Securities and Exchange Commission (the "SEC"), as of the date of this Current Report on Form 8-K, the Company is permitted to sell an aggregate of up to $8,558,712 in Shares under the Agreement, which represents 21.38% of the value of the Company's outstanding common stock held by non-affiliates of the Company.

The Agreement includes customary representations, warranties and covenants by the Company and customary obligations of the parties and termination provisions. The Company has agreed to indemnify the Sales Agent against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the Sales Agent may be required to make with respect to any of those liabilities. The Company will pay the Sales Agent for sales of its common stock a commission of 3.0% of the gross offering proceeds of the Shares sold through the Sales Agent pursuant to the Agreement.

The Shares to be sold under the Agreement, if any, will be issued and sold pursuant to the prospectus forming a part of the Company's shelf registration statement on Form S-3 (File No. 333-287575), which was filed with the SEC on May 23, 2025, and declared effective by the SEC on June 2, 2025, and a prospectus supplement dated November 28, 2025 related thereto, and any successor registration statement filed by the Company with respect to the Shares.

The offering of the Company's common stock pursuant to the Agreement will terminate upon the sale of all of the Shares pursuant to the Agreement, unless sooner terminated in accordance with the terms and conditions of the Agreement.